📰 Preserved Ejection News
Preserved Ejection News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Preserved Ejection. Real-time updates on events, politics, business and more.
April 11, 2024
Deepak Bhatt, MD, MPH, MBA, provides a recap of top trials and new data from the American College of Cardiology's 2024 Annual Scientific Session.
April 9, 2024
The REDUCE-AMI trial found that long-term beta-blocker therapy does not reduce mortality risk in acute myocardial infarction patients with preserved left ventricular ejection fraction compared to no beta-blocker treatment.
April 8, 2024
<p><strong>Half of all patients discharged from hospital after a heart attack are treated with beta-blockers unnecessarily. This is according to a new study published in the New England Journal of Medicine. &quot;I am convinced that this will influence future practice&quot;, says Tomas Jernberg, Professor at Karolinska Institutet and lead researcher of the study.</strong></p>
April 7, 2024
Half of all patients discharged from hospital after a heart attack are treated with beta-blockers unnecessarily. This is according to a new study
December 26, 2023
From newsworthy moments to groundbreaking research, these were the most-read heart failure-related articles on Pharmacy Times in 2023.
October 11, 2023
MATERIAL CHANGE REPORT - Name and Address of Company Cardiol Therapeutics Inc. 2265 Upper Middle Road East, Suite 602 Oakville, Ontario,...
October 10, 2023
Cardiol Therapeutics Inc. , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart...
July 20, 2023
Robert J. Mentz, MD, and Javed Butler, MD, MPH, MBA, comment on the use of beta blockers and other agents in patients with heart failure preserved ejection fraction (HFpEF).
March 30, 2023
This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.
December 12, 2022
AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence extension for dapagliflozin in Great Britain for the treatment of symptomatic chronic heart failure (HF) in patients with HF and a left ventricular ejection fraction (LVEF)